Given that KRAS-mutant cancer cells of distinct tissue origin demonstrated distinct stable resistance programs to ERK inhibition, yet that these programs were universally susceptible to CDK8/19 co-inhibition, we next asked whether there might be a common early response to ERK inhibition vulnerable to combination treatment. This evidence concerns the gene KRAS and cancer.